Medizinische Universität Wien

In-hospital Outcomes of Rotational Atherectomy in ST-Elevation Myocardial Infarction: Results From the Multicentre ROTA-STEMI Network (2024) Hemetsberger R, Mankerious N, Muntané-Carol G, Temporal J, Sulimov D, Gaede L, Woitek F, et al. Journal article Metabolic rewiring promotes anti-inflammatory effects of glucocorticoids (2024) Auger JP, Zimmermann M, Faas M, Stifel U, Chambers D, Krishnacoumar B, Taudte RV, et al. Journal article Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxoedema and scleroedema (2024) Knobler R, Geroldinger-Simić M, Kreuter A, Hunzelmann N, Moinzadeh P, Rongioletti F, Denton C, et al. Journal article Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes (2024) Knobler R, Geroldinger-Simić M, Kreuter A, Hunzelmann N, Moinzadeh P, Rongioletti F, Denton CP, et al. Journal article Regulatory Issues of Platform Trials: Learnings from EU-PEARL (2024) Nguyen QL, Hees K, Hernandez Penna S, König F, Posch M, Bofill Roig M, Meyer EL, et al. Journal article, Review article EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update (2024) Gossec L, Kerschbaumer A, Ferreira RJ, Aletaha D, Baraliakos X, Bertheussen H, Boehncke WH, et al. Journal article Bona fide dendritic cells are pivotal precursors for osteoclasts. (2024) Puchner A, Simader E, Saferding V, Hofmann M, Kieler M, Brunner J, Pfeifle R, et al. Journal article Defining benchmark outcomes for mesial temporal lobe epilepsy surgery: A global multicenter analysis of 1119 cases (2024) Drexler R, Ricklefs FL, Ben-Haim S, Rada A, Wörmann F, Cloppenborg T, Bien CG, et al. Journal article 2023 EULAR recommendations on imaging in diagnosis and management of crystal-induced arthropathies in clinical practice (2024) Mandl P, D'Agostino MA, Navarro-Compán V, Geßl I, Sakellariou G, Abhishek A, Becce F, et al. Journal article A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection. (2024) Mayer KA, Schrezenmeier E, Diebold M, Halloran PF, Schatzl M, Schranz S, Haindl S, et al. Journal article